» Articles » PMID: 22901024

Side Chain Modified Peptide Nucleic Acids (PNA) for Knock-down of Six3 in Medaka Embryos

Overview
Journal BMC Biotechnol
Publisher Biomed Central
Specialty Biotechnology
Date 2012 Aug 21
PMID 22901024
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Synthetic antisense molecules have an enormous potential for therapeutic applications in humans. The major aim of such strategies is to specifically interfere with gene function, thus modulating cellular pathways according to the therapeutic demands. Among the molecules which can block mRNA function in a sequence specific manner are peptide nucleic acids (PNA). They are highly stable and efficiently and selectively interact with RNA. However, some properties of non-modified aminoethyl glycine PNAs (aegPNA) hamper their in vivo applications.

Results: We generated new backbone modifications of PNAs, which exhibit more hydrophilic properties. When we examined the activity and specificity of these novel phosphonic ester PNAs (pePNA) molecules in medaka (Oryzias latipes) embryos, high solubility and selective binding to mRNA was observed. In particular, mixing of the novel components with aegPNA components resulted in mixed PNAs with superior properties. Injection of mixed PNAs directed against the medaka six3 gene, which is important for eye and brain development, resulted in specific six3 phenotypes.

Conclusions: PNAs are well established as powerful antisense molecules. Modification of the backbone with phosphonic ester side chains further improves their properties and allows the efficient knock down of a single gene in fish embryos.

Citing Articles

A Dominant Negative Antisense Approach Targeting β-Catenin.

Vonbrull M, Riegel E, Halter C, Aigner M, Bock H, Werner B Mol Biotechnol. 2018; 60(5):339-349.

PMID: 29524201 PMC: 5918491. DOI: 10.1007/s12033-018-0058-7.


The function of tcf3 in medaka embryos: efficient knockdown with pePNAs.

Doenz G, Dorn S, Aghaallaei N, Bajoghli B, Riegel E, Aigner M BMC Biotechnol. 2018; 18(1):1.

PMID: 29316906 PMC: 5759164. DOI: 10.1186/s12896-017-0411-0.


The genomic and genetic toolbox of the teleost medaka (Oryzias latipes).

Kirchmaier S, Naruse K, Wittbrodt J, Loosli F Genetics. 2015; 199(4):905-18.

PMID: 25855651 PMC: 4391551. DOI: 10.1534/genetics.114.173849.


Chiral peptide nucleic acids with a substituent in the N-(2-aminoethy)glycine backbone.

Sugiyama T, Kittaka A Molecules. 2012; 18(1):287-310.

PMID: 23271467 PMC: 6269907. DOI: 10.3390/molecules18010287.

References
1.
Wittung P, Nielsen P, Buchardt O, Egholm M, Norden B . DNA-like double helix formed by peptide nucleic acid. Nature. 1994; 368(6471):561-3. DOI: 10.1038/368561a0. View

2.
Shiraishi T, Hamzavi R, Nielsen P . Subnanomolar antisense activity of phosphonate-peptide nucleic acid (PNA) conjugates delivered by cationic lipids to HeLa cells. Nucleic Acids Res. 2008; 36(13):4424-32. PMC: 2490735. DOI: 10.1093/nar/gkn401. View

3.
Robu M, Larson J, Nasevicius A, Beiraghi S, Brenner C, Farber S . p53 activation by knockdown technologies. PLoS Genet. 2007; 3(5):e78. PMC: 1877875. DOI: 10.1371/journal.pgen.0030078. View

4.
Koch T, Hansen H, Andersen P, Larsen T, Batz H, Otteson K . Improvements in automated PNA synthesis using Boc/Z monomers. J Pept Res. 1997; 49(1):80-8. DOI: 10.1111/j.1399-3011.1997.tb01124.x. View

5.
Huh S, Hatini V, Marcus R, Li S, Lai E . Dorsal-ventral patterning defects in the eye of BF-1-deficient mice associated with a restricted loss of shh expression. Dev Biol. 1999; 211(1):53-63. DOI: 10.1006/dbio.1999.9303. View